X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Erasca intends to use the net proceeds to fund the research and development of its product candidates and other development programs, including ERAS-254 (naporafenib) administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Product Name: ERAS-254
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 27, 2024
Details:
The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Product Name: ERAS-254
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 14, 2024
Details:
LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Product Name: ERAS-254
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
ERAS-254 (naporafenib) is a potent and selective pan-RAF inhibitor, with a potential first-in-class and best-in-class profile, which is being investigated in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.
Lead Product(s): Naporafenib,Trametinib
Therapeutic Area: Oncology Product Name: ERAS-254
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
ERAS-801 is a highly potent, selective, reversible, and orally available small molecule EGFR inhibitor with significantly enhanced CNS penetration. It is being developed for glioblastoma multiforme.
Lead Product(s): ERAS-801
Therapeutic Area: Oncology Product Name: ERAS-801
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
ERAS-007 is an oral ERK1/2 inhibitor. ERAS-007 + EC was generally well tolerated with mostly low-grade treatment-related adverse events (TRAEs) at all combination doses tested for the treatment of metastatic BRAF V600E- colorectal cancer.
Lead Product(s): ERAS-007,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
ERAS-801 is a highly potent, selective, reversible, and orally available small molecule EGFR inhibitor with significantly enhanced CNS penetration. It is being developed for glioblastoma multiforme.
Lead Product(s): ERAS-801
Therapeutic Area: Oncology Product Name: ERAS-801
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
ERAS-007 is a potential best-in-class ERK1/2 inhibitor being investigated alone or in combination with different inhibitors targeting upstream nodes of the RAS/MAPK pathway as part of Erasca’s MAPKlamp strategy.
Lead Product(s): ERAS-007,ERAS-601
Therapeutic Area: Oncology Product Name: ERAS-007
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
ERAS-3490 also demonstrated robust anti-tumor activity and dose-dependent survival benefit in the KRAS G12C NSCLC intracranial model NCI-H1373-luc, a nonclinical model of NSCLC CNS metastases.
Lead Product(s): ERAS-3490
Therapeutic Area: Oncology Product Name: ERAS-3490
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
LXH254 (naporafenib) is a potent and selective inhibitor of BRAF and CRAF, with a potential first-in-class and best-in-class profile. Erasca plans to focus on securing potential regulatory approval for naporafenib plus trametinib in RAS Q61X tissue agnostic solid tumors.
Lead Product(s): Naporafenib
Therapeutic Area: Oncology Product Name: LXH254
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: $300.0 million Upfront Cash: $300.0 million
Deal Type: Licensing Agreement December 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
